Langin D, Lafontan M
INSERM U.317, Institut de Physiologie, Université Paul Sabatier, Toulouse, France.
Eur J Pharmacol. 1989 Jan 10;159(2):199-203. doi: 10.1016/0014-2999(89)90707-3.
The imidazoline ligand, [3H]idazoxan, labels a large population of high-affinity binding sites in rabbit fat cell membranes (Bmax = 1370 +/- 91 fmol/mg protein; KD = 1.6 +/- 0.6 nM) when imidazoline derivatives are used for definition of non-specific binding. [3H]Idazoxan sites are not alpha 2-adrenoceptors as assessed by competition studies which showed that epinephrine, norepinephrine and yohimbine do not inhibit [3H]idazoxan binding. Naphazoline, tramazoline and the Na+/H+ exchange inhibitor, amiloride, completely inhibited [3H]idazoxan binding. The Ki values were 9, 27 and 48 nM, respectively.
当使用咪唑啉衍生物来定义非特异性结合时,咪唑啉配体[³H]异喹唑能标记兔脂肪细胞膜中大量的高亲和力结合位点(最大结合容量Bmax = 1370 ± 91 fmol/mg蛋白;解离常数KD = 1.6 ± 0.6 nM)。竞争研究表明,肾上腺素、去甲肾上腺素和育亨宾并不抑制[³H]异喹唑的结合,因此[³H]异喹唑位点不是α₂肾上腺素能受体。萘甲唑啉、曲马唑啉以及Na⁺/H⁺交换抑制剂阿米洛利能完全抑制[³H]异喹唑的结合。其抑制常数Ki值分别为9 nM、27 nM和48 nM。